(ONE) Novartis International AG : FDA Expands Age Indication for Menveo®, First and Only Quadrivalent Meningococcal Vaccine

Novartis (NYSE: NVS ) announced today that the US Food and Drug Administration (FDA) approved Menveo^® (Meningococcal Group A, C, W-135 and Y conjugate vaccine) for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and